CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
February 25, 2019 08:02 ET
|
CRISPR Therapeutics AG
-First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- -First patient enrolled in a Phase 1/2 clinical trial of CTX001 for patients with sickle cell...
CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001
February 25, 2019 08:00 ET
|
CRISPR Therapeutics AG
-First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- -First patient enrolled in a Phase 1/2 clinical trial of CTX001 for patients with sickle cell...
CRISPR Therapeutics Proposes New Members to the Board of Directors
February 21, 2019 07:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement
February 19, 2019 07:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass. and Durham, N.C., Feb. 19, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative...
CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies
January 22, 2019 07:00 ET
|
CRISPR Therapeutics AG
CAMBRIDGE, Mass. and BOSTON and BERLIN, Jan. 22, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease
January 04, 2019 07:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Jan. 04, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the...
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
November 21, 2018 07:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 21, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology
November 09, 2018 07:00 ET
|
CRISPR Therapeutics AG
--CRISPR Therapeutics Gains Additional Rights to MaxCyte’s Cell Engineering Technology to Develop CRISPR/Cas9-Based Cell Therapies in Immuno-Oncology-- ZUG, Switzerland and CAMBRIDGE, Mass. and...
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results
November 07, 2018 16:33 ET
|
CRISPR Therapeutics AG
-Initiated Phase 1/2 Clinical Trial of CTX001 in β-thalassemia- -Targeting Initiation of Clinical Trial for CTX110, Targeting CD19+ Malignancies, in 1H 2019--$487.3 Million in Cash as of September 30,...
CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease
October 10, 2018 16:01 ET
|
CRISPR Therapeutics AG; Vertex Pharmaceuticals Incorporated
ZUG, Switzerland and BOSTON and CAMBRIDGE, Mass., Oct. 10, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based...